Drug Trial Radar · NCT00459173
Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation
Last checked: Nov 20, 2026Latest source record: Apr 7, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,850
Actual
Start
Nov 2002
Primary completion
Sep 2005
Study completion Sep 2005
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Apr 11, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg and 20 mg) for the maintenance of abstinence from smoking. Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the clinical and biological safety of 2 doses of rimonabant rimonabant during a 12-month treatment period and to evaluate the pharmacokinetics of the drug.
Conditions
- Maintenance of Smoking Cessation
Interventions
rimonabant (SR141716)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to smoking relapse from the point of re-randomization (Week 10) through Week 32
- Smoking relapse defined as: any 7 or more consecutive days of smoking (even a puff) or any 2 consecutive days of smoking 5 or more cigarettes per day
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
Sanofi-Aventis
Bridgewater, New Jersey
Sanofi-Aventis
Cove, New South Wales, Australia
Sanofi-Aventis
Laval, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.